RecruitingNot Applicable

Cardiovascular and Endothelial Markers During OGTT Before and at Six and Twelve Months Post-treatment in Women With PCOS

Greece120 participantsStarted 2024-02-01

Plain-language summary

The aim of the present study is to investigate a) the presence of subclinical markers of vascular, myocardial and endothelial function in women with PCOS b) the acute alterations in these markers during the oral glucose tolerance test (OGTT) c) the impact of potential treatment interventions in these markers.

Who can participate

Age range18 Years – 45 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age \> 16 years old
✓. Diagonis of PCOS according to Rotterdam criteria: presence of two of the three of the following:
✓. Absence of treatment for PCOS the last six months
✓. Patients who have the ability to understand and sign the consent form.

Exclusion criteria

✕. Disorders with clinical presentation similar to PCOS: thyroid disease, hyperprolactinemia, and non-classic congenital adrenal hyperplasia (primarily 21-hydroxylase deficiency by serum 17-hydroxyprogesterone \[17-OHP\]), Cushing syndrome, acromegaly
✕. Treatment with contraceptive or metformin
✕. Type 2 diabetes mellitus
✕. Treatment for diabetes
✕. Pregnancy
✕. Lactation
✕. Malignancy

What they're measuring

Τhe change in Global Longitudinal Strain during Oral glucose Tolerance Test

Timeframe: 120 minute of Oral glucose Tolerance Test

The change in Pulse Wave Velocity during Oral glucose Tolerance Test

Timeframe: 120minute of Oral glucose Tolerance Test

The change in Perfused Boundary Region during Oral glucose Tolerance Test

Timeframe: 120minute of Oral glucose Tolerance Test

The change in Global Longitudinal Strain

Timeframe: six months

The change in Pulse Wave Velocity

Timeframe: six months

The change in Perfused Boundary Region

Timeframe: six months

The change in Metalloproteinase 9

Timeframe: six months

Trial details

NCT IDNCT06889454

SponsorAttikon Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-02-01

Contact for this trial

VAIA lAMBADIARI, Professor

2105831148 vlambad@otenet.gr

View on ClinicalTrials.gov More PCOS trials

Plain-language summary

Who can participate

Age range18 Years – 45 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age \> 16 years old
✓. Diagonis of PCOS according to Rotterdam criteria: presence of two of the three of the following:
✓. Absence of treatment for PCOS the last six months
✓. Patients who have the ability to understand and sign the consent form.

Exclusion criteria

✕. Disorders with clinical presentation similar to PCOS: thyroid disease, hyperprolactinemia, and non-classic congenital adrenal hyperplasia (primarily 21-hydroxylase deficiency by serum 17-hydroxyprogesterone \[17-OHP\]), Cushing syndrome, acromegaly
✕. Treatment with contraceptive or metformin
✕. Type 2 diabetes mellitus
✕. Treatment for diabetes
✕. Pregnancy
✕. Lactation
✕. Malignancy

What they're measuring

Τhe change in Global Longitudinal Strain during Oral glucose Tolerance Test

Timeframe: 120 minute of Oral glucose Tolerance Test

The change in Pulse Wave Velocity during Oral glucose Tolerance Test

Timeframe: 120minute of Oral glucose Tolerance Test

The change in Perfused Boundary Region during Oral glucose Tolerance Test

Timeframe: 120minute of Oral glucose Tolerance Test

The change in Global Longitudinal Strain

Timeframe: six months

The change in Pulse Wave Velocity

Timeframe: six months

The change in Perfused Boundary Region

Timeframe: six months

The change in Metalloproteinase 9

Timeframe: six months